Skyepharma has announced a partnership agreement with Mundipharma for global development and commercialization of Skyepharma’s SKP-2076 ICS/LABA/LAMA fixed dose combination MDI. Mundipharma, which already markets Skyepharma’s Flutiform fluticasone propionate/formoterol fumarate MDI in Europe and a number of other markets, will pay a non-refundable option fee in the range of “several hundred thousand euros.”
The announcement states that, “Mundipharma has the option, exercisable until shortly after completion of the feasibility work, to complete the development of, and commercialize, SKP-2076 under exclusive global development and licence agreements which the parties have agreed to use good faith and reasonable efforts to negotiate based on heads of terms already established.”
According to Skyepharma, work to formulate SKP-2076 has made “encouraging progress,” and it expects the formulation to be ready for pilot-scale manufacturing in 2016. The company said that it expects feasibility work to be complete by mid-2016.
Skyepharma CEO Peter Grant said, “This new partnership further expands our excellent relationship with Mundipharma based on our successful collaboration on Flutiform, which is growing well in multiple markets. The ICS/LABA/LAMA triple combination is a natural extension of the Flutiform franchise and we believe it has the potential to provide an important additional treatment option for doctors and patients. SKP-2076 is a great example of innovation at Skyepharma, leveraging our expertise and strong relationships with partners to generate benefits for patients and value for shareholders.”
Read the Skyepharma press release.
